Umecrine Cognition
CompanySweden
Umecrine Cognition develops one asset, in phase 1 (golexanolone in primary biliary cholangitis). Mostly small molecule; based in Sweden.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 1
- Signal
Pipeline
1Antagonizes neurosteroid-mediated enhancement of GABA-A receptor signaling.
Phase 1, Small molecule, primary biliary cholangitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals2
- Similar companies6